37525-57-8

Basic information

• Product Name: 2-Mercaptobenzothiazole-4-carboxylic acid
• Synonyms: 2-Mercaptobenzothiazole-4-carboxylic acid;4-Benzothiazolecarboxylicacid,2,3-dihydro-2-thioxo-(9CI)
• CAS NO: 37525-57-8
• Molecular Formula: C8H5NO2S2
• Molecular Weight: 211.26
• Product Categories: BENZOTHIAZOLE
• Mol File: 37525-57-8.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Mercaptobenzothiazole-4-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Mercaptobenzothiazole-4-carboxylic acid(37525-57-8)
• EPA Substance Registry System: 2-Mercaptobenzothiazole-4-carboxylic acid(37525-57-8)

Safety Data

• Hazardous Substances Data: 37525-57-8(Hazardous Substances Data)

Upstream product

• 4771-47-5 3-chloro-2-nitro-benzoic acid 
• 75-15-0 carbon disulfide 
• 20776-55-0 2-amino-3-iodo-benzoic acid 
• 140-89-6 potassium ethyl xanthogenate 

Downstream Products

• 37525-58-9 2-chloro-benzothiazole-4-carbonyl chloride 

Relevant articles and documents

Optimization of Benzothiazole and Thiazole Hydrazones as Inhibitors of Schistosome BCL-2

Limited therapeutic options are available for the treatment of human schistosomiasis caused by the parasitic Schistosoma flatworm. The B cell lymphoma-2 (BCL-2)-regulated apoptotic cell death pathway in schistosomes was recently characterized and shown to share similarities with the intrinsic apoptosis pathway in humans. Here, we exploit structural differences in the human and schistosome BCL-2 (sBCL-2) pro-survival proteins toward a novel treatment strategy for schistosomiasis. The benzothiazole hydrazone scaffold previously employed to target human BCL-XL was repurposed as a starting point to target sBCL-2. We utilized X-ray structural data to inform optimization and then applied a scaffold-hop strategy to identify the 5-carboxamide thiazole hydrazone scaffold (43) with potent sBCL-2 activity (IC50 30 nM). Human BCL-XL potency (IC50 13 nM) was inadvertently preserved during the optimization process. The lead analogues from this study exhibit on-target activity in model fibroblast cell lines dependent on either sBCL-2 or human BCL-XL for survival. Further optimization of the thiazole hydrazone class is required to exhibit activity in schistosomes and enhance the potential of this strategy for treating schistosomiasis.

3-thioheteroaryl cephalosporin compounds, compositions and methods of use

Cephalosporin compounds of the formula I STR1 are disclosed. The compounds are useful against MRSA/MRCNS. Compositions and methods of use are also included.

Carbapenem antibacterial compounds, compositions containing such compounds and methods of treatment

Carbapenems of the formula: STR1 are disclosed as useful antibacterial agents. Pharmaceutical compositions and methods of use are also disclosed.